Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-01-21FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine submitted by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults [Phase 4]
A Phase 4 clinical trial assessing antidepressant response for depressive symptoms and frailty in older adults has been completed with resul…
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors [Phase 1]
Phase 1 clinical trial evaluating psilocybin-assisted group therapy for demoralization in long-term AIDS survivors; completed with results p…
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: A Trauma-Informed Approach for Positive Youth Development for Montana Students [NA]
Clinical trial examining a trauma-informed approach to positive youth development for Montana students has completed with posted results.
-
FDA approval · 2021-01-04FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Bupropion Hydrochloride from Amneal Pharmaceuticals of New York LLC, authorizing the generic pro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-01-04FDA Approved: BUPROPION HYDROCHLORIDE (SR) — Supplemental Application (Cipla USA Inc.,)
The FDA approved Cipla USA Inc.'s supplemental application for Bupropion hydrochloride sustained-release, enabling the generic product to be…
-
FDA approval · 2020-12-31FDA Approved: BUPROPION HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's generic bupropion hydrochloride under an Original Application (ANDA).
-
FDA approval · 2020-12-30FDA Approved: DULOXETINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for duloxetine (ANDA204343), enabling the continued marketing of the gener…
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder [Phase 3]
Phase 3 trial update for brexpiprazole as adjunctive therapy in major depressive disorder has been terminated.
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial update on efficacy, safety and tolerability of agomelatine sublingual tablets for major depressive disorder (MDD) completed.
-
CLINICAL_TRIALS trial_result · 2020-12-24Clinical Trial Update: Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) [Phase 3]
Open-label long-term safety and tolerability study (52 weeks) of agomelatine sublingual tablets in major depressive disorder has terminated …
-
FDA approval · 2020-12-23FDA Approved: FLUOXETINE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved a supplemental application for Fluoxetine from Cadila Pharmaceuticals Limited, enabling the marketing of this generic fluoxetin…
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder [Phase 3]
Phase 3 trial update on agomelatine for major depressive disorder focusing on efficacy, safety, and tolerability.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of agomelatine in preventing relapse of major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) [Phase 3]
Phase 3 clinical trial evaluating agomelatine 25 or 50 mg versus placebo and paroxetine for major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Brainsway DTMS for Treatment of MDD Using iTBS [Phase 4]
Phase 4 clinical trial update for Brainsway DTMS using iTBS in major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder [Phase 3]
Phase 3 trial update on efficacy, safety, and tolerability of agomelatine in treating Major Depressive Disorder.
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of agomelatine sublingual tablets for major depressive disorder has completed.
-
FDA approval · 2020-12-22FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Dr. Reddys Laboratories Inc.)
The FDA approved a supplemental application for Bupropion Hydrochloride SR, granting approval for the generic sustained-release formulation …
-
FDA approval · 2020-12-21FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for bupropion hydrochloride by Aurobindo Pharma Limited.
-
FDA approval · 2020-12-21FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Slate Run Pharmaceuticals, LLC)
The FDA approved a supplemental application for Bupropion hydrochloride sustained-release by Slate Run Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder [Phase 2]
Phase 2 trial evaluating MIN-117 for major depressive disorder has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy [Phase 4]
Phase 4 clinical trial update examining hippocampal volume in young patients with major depressive disorder before and after combined antide…
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels [Phase 4]
A Phase 4 clinical trial assessing how electroconvulsive therapy (ECT) affects homocysteine levels in patients with depressive disorders; co…
-
CLINICAL_TRIALS trial_result · 2020-12-11Clinical Trial Update: Dexmedetomidine Adjuvant Treatment for Depressed Patients Undergoing ECT [Phase 4]
Phase 4 clinical trial investigating dexmedetomidine as an adjuvant treatment for patients with depressive disorders undergoing electroconvu…